{"DataElement":{"publicId":"3653475","version":"1","preferredName":"Patient Primary Neoplasm Recurrent Neoplasm Negative Finding WT1 Protein ER Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"the indicator related to criteria to determine eligibility of patients for medical care programs and services based on primary tumor or recurrent tumor showing a lack of immunoreactivity or negative for expression of WT-1 antigen and Estrogen Receptor antigen.","longName":"Pati_Prim_Recu_Nega_WT1 _ER_Cl","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3653470","version":"1","preferredName":"Patient Primary Neoplasm Recurrent Neoplasm Negative Finding WT1 Protein ER Clinical Trial Eligibility Criteria","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services based on primary tumor or recurrent tumor showing lack of immunoreactivity or negative for expression of WT-1 antigen (a potential regulator of transcription, WT1 belongs to the EGR family of C2H2 zinc-finger proteins and binds to the DNA sequence 5'-CGCCCCCGC-3') and Estrogen Receptor (cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain) antigen.","longName":"Pati_Prim_Recu_Nega_WT1 _ER_Cl","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3653468","version":"1","preferredName":"Primary Neoplasm Recurrent Neoplasm Negative Finding WT1 Protein ER Clinical Trial Eligibility Criteria","preferredDefinition":"The original tumor.:The reemergence of neoplasm after a period of remission:A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.:A potential regulator of transcription, WT1 belongs to the EGR family of C2H2 zinc-finger proteins and binds to the DNA sequence 5'-CGCCCCCGC-3'. Inactivation of WT1 is one cause of Wilm's Tumor, an embryonal malignancy of the kidney. Defects in WT1 are also associated with Denys-Drash Syndrome (DDS) and Diffuse Mesangial Sclerosis (DMS). (from SWISS-PROT P19544, OMIM 194070, and NCI):Widely expressed human Estrogen Receptors (NR3 Family) are ligand-activated nuclear hormone receptor transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI):Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3653468v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Neoplasm","conceptCode":"C8509","definition":"A tumor at the original site of origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Recurrent Neoplasm","conceptCode":"C4798","definition":"The reemergence of a neoplasm after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Wilms Tumor Protein","conceptCode":"C17549","definition":"Wilms tumor protein (449 aa, ~49 kDa) is encoded by the human WT1 gene. This protein is involved in transcriptional regulation, embryonic morphogenesis and in both tumor suppression and tumorigenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Estrogen Receptor Family","conceptCode":"C17069","definition":"Widely expressed human Estrogen Receptors (NR3 Family) are cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-84F1-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-8502-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3653472","version":"1","preferredName":"Primary Recurrent Neoplasm Negative Finding WT1 Protein Indicator","preferredDefinition":"the indicator related to a condition that characterizes whether the tumor showing a lack of expression of WT-1 antigen Estrogen Receptor antigen is based on primary or recurrent disease.","longName":"Pri_Rec_Neg_Find_Prot_Ind","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D393E2D1-853E-C573-E040-BB89AD431BF0","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","deletedIndicator":"No"},{"value":"Yes-Recurrent","valueDescription":"Recurrent Neoplasm Yes","ValueMeaning":{"publicId":"3653473","version":"1","preferredName":"Recurrent Neoplasm Yes","longName":"3653473","preferredDefinition":"The reemergence of neoplasm after a period of remission: The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Neoplasm","conceptCode":"C4798","definition":"The reemergence of a neoplasm after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-854B-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D393E2D1-8564-C573-E040-BB89AD431BF0","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","deletedIndicator":"No"},{"value":"Yes-Primary","valueDescription":"Primary Neoplasm Yes","ValueMeaning":{"publicId":"3653474","version":"1","preferredName":"Primary Neoplasm Yes","longName":"3653474","preferredDefinition":"The original tumor.: The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Neoplasm","conceptCode":"C8509","definition":"A tumor at the original site of origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-8571-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D393E2D1-858A-C573-E040-BB89AD431BF0","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-852A-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"REEVESD","dateModified":"2014-08-17","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000276","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104930","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"10000275","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104938","version":"1","longName":"GOG-0254","context":"NRG"}]}],"AlternateNames":[{"name":"Pati_Prim_Recu_Nega_WT1 _ER_Cl","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Are there representative stai","type":"Preferred Question Text","description":"Are there representative stained slides available from the primary or recurrent/persistent tumor showing lack of immunoreactivity or negative for expression of WT-1 antigen and Estrogen Receptor (ER) antigen by immunohistochemsitry?","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-8594-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}